Tech Company Financing Transactions

XyloCor Therapeutics Funding Round

XyloCor Therapeutics closed a $41.9 million Series A venture capital round on 3/24/2021. Backers included Fountain Healthcare Partners, Life Sciences Partners and Longwood Fund.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

76 Longview Ln.
Newtown Square, PA 19073
USA

Phone

(888) 290-0081

Website

www.xylocor.com

Email Address

[email protected]

Overview

XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. Our lead product candidate, XC001, is in clinical development for patients with refractory angina for which there are no treatment options.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Albert Gianchetti

        

Chief Medical Officer

Rickey Reinhardt

        

VP - Finance

Michael Carson

        

VP - Manufacturing

Alexander Gaidamaka

        

VP - Operations

Dawn Byrnes

        

VP - R & D

Howard Dittrich

        

Browse more venture capital transactions:

Prev: 3/24/2021: Lev venture capital transaction
Next: 3/24/2021: Meatable venture capital transaction

Share this article

Where The Data Comes From

We do our best to record every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary